Neoadjuvant chemoradiation for adenocarcinoma of the pancreas

A. R. Miller, E. K. Robinson, J. E. Lee, P. W.T. Pisters, P. J. Chiao, R. Lenzi, J. L. Abbruzzese, D. B. Evans

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations

Abstract

Pancreaticoduodenectomy is performed on carefully selected patients as part of a protocol-based clinical research program emphasizing the importance of multimodality management for patients with potentially resectable adenocarcinoma of the pancreatic head. Treatment schemas emphasize the importance of minimizing toxicity and treatment duration, while attempting to improve therapeutic efficacy. Cytotoxicity is enhanced by combining radiation therapy with more potent radiation-sensitizing agents. Because of the high incidence of liver metastases, systemic therapy is continued after chemoradiation and surgery with systemic agents of low toxicity directed at specific molecular events involved in pancreatic tumorigenesis such as inhibition of angiogenesis, induction of apoptosis, or arrest of the cell cycle.

Original languageEnglish (US)
Pages (from-to)183-197
Number of pages15
JournalSurgical oncology clinics of North America
Volume7
Issue number1
DOIs
StatePublished - 1998

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Neoadjuvant chemoradiation for adenocarcinoma of the pancreas'. Together they form a unique fingerprint.

Cite this